Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol + Toripalimab + Chemotherapy in Resectable NSCLC
NCT07886229Phase 1Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Incidence and Severity of Adverse Events at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
propranolol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07886229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886229.